Delving into the Latest Updates on Butenafine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(4-tert-Butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine, 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine

+ [30]

Target

SQLE

Mechanism

SQLE inhibitors(Squalene monooxygenase inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Skin Diseases, InfectiousTinea corporistinea cruris+ [2]

Inactive Indication

Allergic skin reactionDermatitis, PhotoallergicDermatitis, Phototoxic

Originator Organization

Kaken Pharmaceutical Co., Ltd.

Active Organization

Kaken Pharmaceutical Co., Ltd.Bayer Healthcare LLC

Hisamitsu Pharmaceutical Co., Inc.

+ [2]

Inactive Organization

Bayer AGMylan Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (21 Jan 1992),

Tinea corporistinea crurisTinea Pedis+ [1]

Regulation-

Login to view timeline

Structure

Molecular FormulaC23H28ClN

InChIKeyLJBSAUIFGPSHCN-UHFFFAOYSA-N

CAS Registry101827-46-7

View All Structures (2)

Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis of tinea pedia involves clinical symptoms as well as microscopic examination. Topical therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control in adult Filipino patients with athlete's foot. This study will benefit the Filipino community by helping us determine which anti-fungal cream is most effective for athlete's foot.

Start Date02 Jan 2019

Sponsor / Collaborator

United Laboratories, Inc.

NCT04531540 / CompletedPhase 3

HT201321- Repeated Insult Patch Test With Modified Challenge

In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions. The study plans to enroll about 225 female or male participants with the age 18 - 79 years. The antifungal test cream will be applied on the back between the shoulder blades of the participants and covered by a special dressing patch. This will be repeated 3 times a week for the first 3 weeks of this study applying the cream on the same area of the back. At each visit the skin will be investigated for redness, dryness and other reactions. After a rest period of two weeks the test cream will be applied on the same skin area as before and on a second new skin area nearby. After 2 and 4 days the two skin areas will again be investigated for redness, dryness and other reactions.

Start Date09 Sep 2013

Sponsor / Collaborator

Bayer AG

NCT04531527 / CompletedPhase 3

HT201308- Human Phototoxicity Test

In this study researchers want to gather information about the potential of Antifungal Cream V61-044 containing Trolamine to produce a phototoxic reaction on the skin. A phototoxic reaction is an irritant reaction of the skin to ultra violet light. In order to find this out the study drug will be applied to the skin of healthy human subjects. By using a solar simulator to generate a UV spectrum similar to that of sunlight the potential of the study drug to produce a superficial reddening of the skin will be measured.

Start Date24 Jun 2013

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Butenafine Hydrochloride

Login to view more data

100 Translational Medicine associated with Butenafine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Butenafine Hydrochloride

Login to view more data

111

Literatures (Medical) associated with Butenafine Hydrochloride

01 Dec 2024·Fundamental & Clinical Pharmacology

Nociceptive TRP channels function as molecular target for several antifungal drugs

Article

Author: Hashimoto, Miho ; Okabe, Shota ; Ohta, Toshio ; Takahashi, Kenji

AbstractBackground/objectivesTopically applied antifungal agents can induce adverse effects, such as pain and irritation. The transient receptor potential (TRP) channels—TRPA1 and TRPV1—mainly expressed in sensory neurons, act as sensors for detecting irritants. This study aims to evaluate the involvement of nociceptive channels in topical antifungal‐induced pain and irritation. We tested nine topical antifungals belonging five classes: isoconazole, econazole, miconazole, clotrimazole, and ketoconazole as imidazoles; liranaftate as a thiocarbamate; terbinafine as an allylamine; amorolfine as a morpholine; and butenafine as a benzylamine.MethodsIntracellular calcium concentrations ([Ca2+]i) and membrane currents in response to antifungals were measured to estimate channel activity using heterologously expressing cells and isolated mouse sensory neurons.ResultsIn mouse TRPA1‐expressing cells, all the tested drugs induced an increase in [Ca2+]i, which was abrogated or reduced by a TRPA1 blocker. Although many drugs evoked the TRPA1‐nonspecific [Ca2+]i response at high concentrations, responses to clotrimazole, ketoconazole, and liranaftate were TRPA1 specific and elicited current responses in TRPA1‐expressing cells. In mouse TRPV1‐expressing cells, clotrimazole and ketoconazole elicited [Ca2+]i and current responses. In mouse sensory neurons, liranaftate‐induced increase in [Ca2+]i was abrogated by a TRPA1 blocker and Trpa1 deletion. Responses to ketoconazole were inhibited by TRPA1 and TRPV1 blockers and by the genetic deletion of either channel.ConclusionThese results suggest that topical antifungal‐induced pain and irritation are attributable to the activation of nociceptive TRPA1 and/or TRPV1 channel/s. Consequently, caution should be exercised in the use of topical antifungals with symptoms of pain.

01 Mar 2024·European review for medical and pharmacological sciences

In vitro antifungal susceptibility of the dermatophytes: a single center study from Eastern Black Sea Region of Turkey.

Article

Author: Direkel, Ş ; Oğuz, I D ; Akşan, B ; Aksoy, S ; Kulakli, S

OBJECTIVEA large number of patients applying to the dermatology clinics are affected by fungal diseases, and a significant portion of which are superficial fungal infections. Dermatophyte infections are a notable public health concern and frequently encountered in clinical practice. Dermatophytosis not only compromises the quality of life but also predisposes individuals to various comorbidities due to its role as a gateway for secondary bacterial agents. This study aims to determine the species distribution of dermatophytes prevalent and assess their susceptibility to antifungal drugs.PATIENTS AND METHODSSkin, nail, and hair samples were obtained from patients with a clinical diagnosis of dermatophytosis. Samples were all cultured to isolate and identify the species. In vitro liquid microdilution tests were conducted to assess the susceptibility of the isolated strains against terbinafine, fluconazole, griseofulvin, and butenafine.RESULTSA total of 353 samples were obtained from the hair, skin, and nail lesions of 326 patients. Dermatophyte was isolated in 71 of the samples (20.1%). The cultured dermatophyte subtypes included Trichophyton rubrum (13.8% in 49 samples), Microsporum audouini (5.7% in 20 samples), and Trichophyton mentagrophytes (0.6% in 2 samples). Antifungal susceptibility testing revealed that terbinafine was the most effective antifungal drug against all dermatophyte species, while fluconazole exhibited the highest resistance.CONCLUSIONSThe most common dermatophytosis agent in our region is T. rubrum. The least antifungal resistance was found against terbinafine. Conducting antifungal susceptibility tests is crucial for selecting effective treatment regimens and early detection of resistance development.

01 Jan 2024·European Journal of Pharmaceutical Sciences

Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: In Vitro and In Vivo study

Article

Author: Liang, Zhen ; Zhang, Zhen ; Lu, Ping ; Zhang, Junjie ; Zhou, Tianyang ; Song, Fei ; Yang, Jingjing ; Li, Jingguo

Fungal keratitis (FK) is a serious infectious corneal disease that leads to blindness. Butenafine (BTF) is an allylamine drug with high antifungal activity, but its poor water solubility and low bioavailability limit its clinical application in ophthalmology. To increase its aqueous solubility and corneal permeability, butenafine was encapsulated in d-ɑ-tocopheryl polyethylene glycol succinate (TPGS) polymeric nanomicelles to improve the bioavailability of the drug for the treatment of FK. Butenafine was successfully fabricated into nanomicelles with a high EE of 96.34 ± 1.65 % and DL of 6.71 ± 0.099 %. The BTF-NM showed an average particle size of 13.12 ± 0.24 nm, a zeta potential of -0.56 ± 0.44 mV and a narrow PDI of 0.12 ± 0.02 with a nearly spherical shape. The characterization results of FTIR, XRD and DSC indicated that BTF was encapsulated in the TPGS nanomicelles. The BTF-NM formulation also showed high storage stability, and the in vitro drug release study showed typical biphasic-release characteristics. In addition, the BTF-NM formulation displayed good cellular tolerance and excellent ocular tolerance in rabbits. Significantly elevated in vitro antifungal activity was also observed in the BTF-NM formulation, and remarkable improvements regarding in vivo corneal permeation were observed compared with the BTF suspension formulation. Finally, the in vivo antifungal activity studies indicated that the BTF-NM formulation had a good therapeutic effect on FK and had similar efficacy to that of commercial natamycin suspension eye drops. These results suggest that the BTF-NM ophthalmic formulation could be a promising ocular drug delivery system for the treatment of FK.

100 Deals associated with Butenafine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01093	Butenafine Hydrochloride	D01AE23	DB01091

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Skin Diseases, Infectious	CN	Sichuan Medshine Pharmaceutical Co.	14 Jan 2002
Tinea corporis	JP	Kaken Pharmaceutical Co., Ltd.	21 Jan 1992
Tinea corporis	JP	Hisamitsu Pharmaceutical Co., Inc.	21 Jan 1992
tinea cruris	JP	Hisamitsu Pharmaceutical Co., Inc.	21 Jan 1992
tinea cruris	JP	Kaken Pharmaceutical Co., Ltd.	21 Jan 1992
Tinea Pedis	JP	Kaken Pharmaceutical Co., Ltd.	21 Jan 1992
Tinea Pedis	JP	Hisamitsu Pharmaceutical Co., Inc.	21 Jan 1992
Tinea Versicolor	JP	Kaken Pharmaceutical Co., Ltd.	21 Jan 1992
Tinea Versicolor	JP	Hisamitsu Pharmaceutical Co., Inc.	21 Jan 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Phototoxic	Phase 2	US	Bayer AG	24 Jun 2013
Allergic skin reaction	Phase 2	US	Bayer AG	10 Jun 2013
Dermatitis, Photoallergic	Phase 2	US	Bayer AG	10 Jun 2013
Mycoses	Phase 2	US	Bayer AG	10 Jun 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04532164 (CTgov)	Phase 3	Mycoses \| Allergic skin reaction \| Dermatitis, Photoallergic	137	Butenafine HCl 1% (BAY1896425) - Challenge Phase	imhimlvdzm(gkfljkoidr) = hkhwtyzcwb sxfswzdvas (ylnljtpvqk, lizgwjtwxa - fwcmkdkjfi) View more	-	16 Nov 2020
NCT04531813 (CTgov)	Phase 3	Hypersensitivity \| Skin Diseases	32	Negative Control+Butenafine HCl 1% (BAY1896425)	wrkkegdfjz(qqkrvoxkax) = kegcvlpzlo atkrdcajet (fxxjyanhmx, vgdoudcfxx - usxmtpuxol) View more	-	25 Sep 2020
NCT04531540 (CTgov)	Phase 3	Hypersensitivity \| Central Sensitizations \| Skin Diseases	225	Butenafine HCl 1% (BAY1896425)	xoupodqwlm(fliitkbamd) = kkawtdxxcy bzohjgeatj (lqrqiykipa, gezqhrlfez - blzxmhfquc) View more	-	25 Sep 2020
NCT04531527 (CTgov)	Phase 3	Dermatitis, Phototoxic	32	Butenafine HCl 1% (BAY1896425)	potgmkwyeu(qfshwcdyns) = ignozoburp okhrwcmqas (frtieazrhr, ecrnuvrcgg - xlxzulafvp) View more	-	21 Sep 2020
NCT00835510 (CTgov)	Phase 1	Tinea Pedis	548	Butenafine cream 1% manufactured by Taro (Butenafine Cream 1% (Taro))	rjpxnuvovt(ztknqlphjt) = tynjqisgzm vypppgsxos (qqxxhbqlcp, jrlsatmury - abacqmmbwu) View more	-	06 Oct 2009
NCT00835510 (CTgov)	Phase 1	Tinea Pedis	548	Lotrimin Ultra (butenafine) 1% (Lotrimin Ultra (Butenafine) 1%)	rjpxnuvovt(ztknqlphjt) = rvwpoxmzdq vypppgsxos (qqxxhbqlcp, gpnkggfniz - bdaiowrhiz) View more	-	06 Oct 2009